Amatsigroup, a contract development and manufacturing organization based in Toulouse, France, has acquired Q-Biologicals, a Belgian contract provider of biologics process development and biomanufacturing services for research and clinical development.

Founded in 2011, Q-Biologicals is a provider of process development and biomanufacturing services, specializing in biologicals used in therapeutics, vaccines and diagnostics, such as recombinant proteins, antibodies, viruses and living cells. Spin-off from the Flemish Institute of Biotechnology (VIB) and Ghent University (UGent), Q-Biologicals is based in Ghent in Belgium. The company has 20 employees with turnover of EUR 4 million in 2015.

Amatsigroup, founded in 2010, was formed through the merger of four companies (Avogadro, Amatsi, DBI, Avepharm). As of 2014, Amatsigroup began to expand internationally with the acquisition of its subsidiaries SEPS Pharma in Belgium and Amatsigroup Inc. (Indiana, US). Its international expansion continued in 2015 with the acquisition of Pierre Fabre's pharmaceutical analysis laboratory in Saint-Augustin, France. The company had 2015 revenues of EUR 33 million and has 240 employees.

Source: Amatsigroup